SWS. Fadilah Abdul Wahid

S. Fadilah Abdul Wahid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. Fadilah Abdul Wahid has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Nor Asiah Muhamad

    Sector for Evidence‐based Healthcare National Institutes of Health Ministry of Health Malaysia Putrajaya Malaysia

    2 shared publications
  • Abdul Aziz Baba

    School of Medicine, International Medical University, Kuala Lumpur, Malaysia

    1 shared publication
  • Ahlam Naila Kori

    Department of Medical Hospital Tengku Ampuan Afzan Kuantan Malaysia

    1 shared publication
  • Azizan Sharif

    Haematology Unit, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia

    1 shared publication
  • Azlan Husin

    Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia

    1 shared publication
  • Chiang Su Kien

    Department of Medicine Haematology Unit Hospital Pulau Pinang Penang Malaysia

    1 shared publication

Latest Publications

  • Open Access

    Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial

    by Sze-Piaw Chin, Sen Mui Tan, Kian Meng Chang, S Fadilah Abdul Wahid, Azizan Sharif, Nik Syazana Izyan Saffery, Sharifah Shahnaz Syed Abd Kadir, Kim Wah Ho, Kong Yong Then, Soon Keng Cheong

    Background: A major challenge after allogeneic haematopoietic stem cell transplantation for haematologic malignancies is the management of acute graft-versus-host disease (aGVHD), which remains associated with poor prognosis despite therapeutic advancements. We conducted a randomized, double-blinded, placebo-controlled Phase I/II clinical trial to assess the safety and efficacy of umbilical cord-derived mesenchymal stem cells (Cyto-MSC) as an upfront treatment in patients with grade II–IV aGVHD. Methods: In this multicentre trial, 22 grade II–IV aGVHD patients were randomized to receive up to three infusions of Cyto-MSC (n = 14) or placebo (n = 8), alongside standard corticosteroid therapy. The primary endpoints were overall response (OR) at Day 28 and overall survival (OS) at 12 months. The secondary endpoints included correlation between responses at Day 28 with 12-month OS and exploratory analyses of immune cell subsets. Results: No treatment-related adverse events were observed. There were no significant differences between Cyto-MSC and placebo in the OR at Day 28 and 12-month OS. Among patients with severe grade III–IV aGVHD who achieved OR by Day 28, those treated with Cyto-MSC had significantly improved 12-month OS compared to placebo (100% vs 50%, p=0.039). Furthermore, in patients with severe aGVHD and baseline CD4+ TEMRA > 35% or CD8+ TEMRA > 70%, the survival benefit was pronounced in the Cyto-MSC group (83.3% and 100%, respectively). In contrast, none of the placebo-treated patients with baseline CD4+ TEMRA < 35% (p=0.007) or CD8+ TEMRA < 70% (p=0.005) survived at 12 months. OS was significantly associated with OR at Day 28 (p< 0.001), baseline CD4⁺ TEMRA (p=0.004), and baseline CD8⁺ TEMRA (p=0.004). Conclusion: Patients with severe grade III–IV aGVHD, particularly those who respond early or have elevated baseline CD4+ TEMRA (> 35%) or CD8+ TEMRA (> 70%) levels, may have an overall survival advantage when treated with Cyto-MSC as an upfront therapy in combination with standard corticosteroids.


  • A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia

    by S. Fadilah Abdul Wahid, Nor Asiah Muhamad, Nor Azimah Ismail, Izzah Athirah Rosli, Chiang Su Kien, Soo Min Lim, Lee Ping Chew, Kirubamoorthy Kamini, Veena Selvaratnam, Ahlam Naila Kori, et al.

    Background: Polatuzumab vedotin + bendamustine + rituximab (Pola‐BR) was recently approved in Malaysia for treating relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). A multicenter retrospective study was conducted to assess the effectiveness of this regimen among patients in a compassionate use program. Objective: To determine treatment response and survival rates for R/R DLBCL patients treated with Pola‐BR in Malaysia. Methodology: Safety and efficacy data of 23 adults with R/R DLBCL treated with Pola‐BR at nine centers in Malaysia (September 2019–February 2021) were used. Of the 23 patients, 13 received six cycles of Pola‐BR. The median follow‐up was 10 months (1–37 months). The primary endpoint was complete response (CR) rate; secondary endpoints were overall survival (OS), progression‐free survival (PFS), and adverse events (AEs). Results: The overall response rate was 56.5%, with 34.8% achieving CR. The 1‐, 2‐, and 3‐year OS rates were 51.6%, 51.6%, and 44.2%, respectively, with a median OS of 27 months. The 1‐ and 2‐year PFS rates were 48.2% and 41.3%, respectively, with a median PFS of 10 months; 60% of the nonresponders had progressive disease. Cox proportional hazard regression analysis showed that bulky disease was a significant hazard for disease progression. A total of 42 AEs were recorded, of which 66.7% were grade ≥ 3 AEs; 90.5% of the AEs were hematological and resolved with treatment; only one patient succumbed to neutropenic sepsis. Conclusions: Pola‐BR has a favorable safety profile for R/R DLBCL treatment in Malaysia, although larger sample sizes and longer follow‐ups are needed to confirm these results.


  • Open Access

    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia

    by S. Fadilah Abdul Wahid, Nor Azimah Ismail, Muhammad Firdaus Md Fauzi, Mohd Razif Mohd Idris, Mohd Syahrir Yusop, Timothy Lim, Nor Asiah Muhamad


  • Open Access

    HOXA4Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients

    by Marjanu Hikmah Elias, Abdul Aziz Baba, Azlan Husin, Sarina Sulong, Rosline Hassan, Goh Ai Sim, S. Fadilah Abdul Wahid, Ravindran Ankathil

    Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor genes correlates with disease progression in some CML patients treated with IM suggests a relationship between epigenetic silencing and resistance development. We hypothesize that promoter hypermethylation ofHOXA4could be an epigenetic mechanism mediating IM resistance in CML patients. Thus a study was undertaken to investigate the promoter hypermethylation status ofHOXA4in CML patients on IM treatment and to determine its role in mediating resistance to IM. Genomic DNA was extracted from peripheral blood samples of 95 CML patients (38 good responders and 57 resistant) and 12 normal controls. All samples were bisulfite treated and analysed by methylation-specific high-resolution melt analysis. Compared to the good responders, theHOXA4hypermethylation level was significantly higher (P=0.002) in IM-resistant CML patients. On comparing the risk,HOXA4hypermethylation was associated with a higher risk for IM resistance (OR 4.658; 95% CI, 1.673–12.971;P=0.003). Thus, it is reasonable to suggest that promoter hypermethylation ofHOXA4gene could be an epigenetic mechanism mediating IM resistance in CML patients.


  • Cord Blood CD34 + Cells Cultured with FLT3L, Stem Cell Factor, Interleukin-6, and IL-3 Produce CD11c + CD1a − /c − Myeloid Dendritic Cells

    by S.A.W. Fadilah, S. Vuckovic, D. Khalil, D.N.J. Hart

    Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34(+) cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c(+)CD16() CD1a()/c() MDCs from CB CD34(+) cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33(+)CD14()CD15() precursors with a mean of 4 x 10(6) cells generated from 1-4 x 10(4) CB CD34(+) cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34(+) cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.